Vertex Pharmaceuticals Incorporated
Materials and methods for treatment of hemoglobinopathies
Last updated:
Abstract:
Materials and methods for treating a patient with hemoglobinopathy, both ex vivo and in vivo and materials and methods for deleting at least a portion of a human beta globin locus on chromosome 11 in a human cell by genome editing and thereby increasing the production of fetal hemoglobin (HbF).
Status:
Grant
Type:
Utility
Filling date:
5 Feb 2019
Issue date:
8 Mar 2022